Avenue Therapeutics, Inc. (ATXI)
OTCMKTS · Delayed Price · Currency is USD
0.5000
+0.1400 (38.89%)
Sep 24, 2026, 4:00 PM EST
Avenue Therapeutics Revenue
In the year 2025, Avenue Therapeutics had annual revenue of $1.40M.
Revenue
1.40M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
1.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Helix BioMedix | 2.07M |
| Vaccinex | 601.00K |
| AXIM Biotechnologies | 92.90K |
| Enzolytics | 46.59K |
| VitaSpring Biomedical | -1.49M |
Avenue Therapeutics News
- 7 weeks ago - Avenue Therapeutics Quarterly report: Q2 2026 - Filings
- 4 months ago - Avenue Therapeutics Quarterly report: Q1 2026 - Filings
- 5 months ago - Avenue Therapeutics Annual report: Q4 2025 - Filings
- 7 months ago - Avenue Therapeutics enters worldwide license agreement for ATX-04 - TheFly
- 8 months ago - Avenue Therapeutics Transcript: AGM 2025 - Transcripts
- 9 months ago - Avenue Therapeutics Proxy statement: Proxy Filing - Filings
- 10 months ago - Avenue Therapeutics Quarterly report: Q3 2025 - Filings
- 10 months ago - Avenue Therapeutics announces Baergic Bio acquisition by Axsome - TheFly